Indeed, researchers are looking for inhibitors of NOX2 as a novel therapeutic class of drugs to treat diseases such as AD, PD, cardiovascular diseases, and many other different diseases where oxidative stress and inflammation are key drivers. This evidence concerns the gene CYBB and Parkinson disease.